However, trust gaps among clinicians and patients are threatening to slow the adoption and impact of AI. Among HCPs, ...

Join the 4th Process Development for Cell Therapies Summit to hear from 24+ industry leaders from biopharma and service ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has made his first testimonies in front of Congress since he ...

Since December 2022, and COP decision 15/9, members of the Convention on Biological Diversity (the CBD) have been negotiating ...

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...

Despite significant R&D investments, pharma companies often underestimate the multifaceted challenges of bringing promising treatments to market – from securing favourable reimbursement to ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.

There’s a common public perception of pharma executives as callous, money-hungry suits who want as many people to be sick as possible – so they’ll pay as much as possible for their drugs.